Key Points
- Director Gregory Lucier purchased 15,000 shares on March 9 at an average price of $12.45 (total $186,750), boosting his stake 30% to 65,000 shares valued at about $809,250.
- The company slightly missed quarterly EPS ($0.27 vs. $0.28 consensus) while revenue rose 6.2% to $961M, and management set FY2026 guidance of $1.40–$1.50 EPS.
- Dentsply declared a $0.16 quarterly dividend (a 5.0% yield) and has seen multiple analyst target upgrades, though the consensus rating remains "Hold" with an average target of $14.42.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) Director James Forbes acquired 5,000 shares of the company's stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $12.48 per share, with a total value of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
DENTSPLY SIRONA Stock Performance
DENTSPLY SIRONA stock opened at $12.80 on Tuesday. The company's 50-day moving average price is $12.66 and its 200-day moving average price is $12.44. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The company has a market cap of $2.56 billion, a PE ratio of -4.27, a price-to-earnings-growth ratio of 1.49 and a beta of 0.97. DENTSPLY SIRONA Inc. has a twelve month low of $9.85 and a twelve month high of $17.18.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). The business had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.
DENTSPLY SIRONA Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA's dividend payout ratio (DPR) is presently -21.33%.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on XRAY shares. UBS Group cut their target price on DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Robert W. Baird lifted their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday, February 27th. Barrington Research boosted their price objective on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an "outperform" rating in a research report on Monday, March 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Finally, Wells Fargo & Company lifted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 27th. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $14.42.
View Our Latest Report on XRAY
Hedge Funds Weigh In On DENTSPLY SIRONA
A number of large investors have recently bought and sold shares of the business. Eurizon Capital SGR S.p.A. bought a new position in DENTSPLY SIRONA in the 4th quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA during the first quarter worth $26,000. Parkside Financial Bank & Trust lifted its position in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 1,477 shares during the last quarter. Huntington National Bank boosted its stake in shares of DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,077 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,122 shares during the period. Hedge funds and other institutional investors own 95.70% of the company's stock.
About DENTSPLY SIRONA
(
Get Free Report)
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
